The vaccine that has so far been approved for use in the U.S. is based on RNA, a relatively new vaccine technology. The vaccine delivers information on RNA molecules, which are inherently unstable. That’s partly why they need to be kept at extremely cold temperatures. Corey Casper, President and CEO of the Infectious Disease Research Institute in Seattle, explains the challenges in delivering these new vaccines to everyone who needs them.